US19249J3077 - Common Stock - After market: 2.77 +0.04 (+1.47%)
NASDAQ:CWBR (2/3/2023, 5:40:59 PM)-0.13 (-4.55%)
|GICS Sector||Health Care|
|Earnings (Last)||11-08 2022-11-08/amc||Earnings (Next)||03-27 2023-03-27|
|Ins Owners||7.17%||Inst Owners||0.26%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm focuses on developing therapeutics targeting chronic and age-related diseases. The company is advancing a pipeline of peptide analogs through varying stages of development, such as CB5138-3 for idiopathic pulmonary fibrosis (IPF); CB4211 for the treatment of non-alcoholic steatohepatitis (NASH) and obesity; and several preclinical and discovery-stage programs. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing, and optimizing analogs of these natural mitochondrial derived peptides (MDPs), as well as developing and conducting screens to identify and characterize the activities of these peptides are referred to its Mito+ platform. The company is using its Mito+ platform to identify and develop modified versions of natural peptides called analogs, to treat a range of serious conditions, with a focus on chronic diseases involving inflammation and fibrosis.
1455 Adams Drive, Suite 2050
Menlo Park CALIFORNIA 94025
CEO: Steven Engle
Conference call and webcast today at 5:00 p.m. ET, November 8, 2022
Conference call and webcast today at 5:00 p.m. ET, November 8, 2022...
Company to host conference call and webcast at 5:00 p.m. ET
Company to host conference call and webcast at 5:00 p.m. ET...
With more pain ahead for equities, these seven Nasdaq stocks should be the first to be expelled from investors' portfolios.
MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the...
Here you can normally see the latest stock twits on CWBR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.